TY - JOUR
T1 - Advances in Hybrid Vesicular-based Drug Delivery Systems
T2 - Improved Biocompati-bility, Targeting, Therapeutic Efficacy and Pharmacokinetics of Anticancer Drugs
AU - Setia, Aseem
AU - Sahu, Ram Kumar
AU - Ray, Supratim
AU - Widyowati, Retno
AU - Ekasari, Wiwied
AU - Saraf, Swarnlata
N1 - Publisher Copyright:
© 2022 Bentham Science Publishers.
PY - 2022/8
Y1 - 2022/8
N2 - Anticancer drugs and diagnostics can be transported in nanoscale vesicles that provide a flexible platform. A hybrid nanoparticle, a nano assembly made up of many types of nanostructures, has the greatest potential to per-form these two activities simultaneously. Nanomedicine has shown the promise of vesicular carriers based on lipo-polymersomes, lipid peptides, and metallic hybrid nano-vesicle systems. However, there are significant limitations that hinder the clinical implementation of these systems at the commercial scale, such as low productivity, high ener-gy consumption, expensive setup, long process durations, and the current cancer therapies described in this article. Combinatorial hybrid systems can be used to reduce the above limitations. A greater therapeutic index and improved clinical results are possible with hybrid nanovesicular systems, which integrate the benefits of many carriers into a single structure. Due to their unique properties, cell-based drug delivery systems have shown tremendous benefits in the treatment of cancer. Nanoparticles (NPs) can benefit significantly from the properties of erythrocytes and plate-lets, which are part of the circulatory cells and circulate for a long time. Due to their unique physicochemical proper-ties, nanomaterials play an essential role in cell-based drug delivery. Combining the advantages of different nano-materials and cell types gives the resulting delivery systems a wide range of desirable properties. NPs are next-generation core-shell nanostructures that combine a lipid shell with a polymer core. The fabrication of lipid-polymer hybrid NPs has recently undergone a fundamental shift, moving from a two-step to a one-step technique based on the joint self-assembly of polymers and lipids. Oncologists are particularly interested in this method as a combinatorial drug delivery platform because of its two-in-one structure. This article addresses various preparative methods for the preparation of hybrid nano-vesicular systems. It also discusses the cellular mechanism of hybrid nano-vesicular systems and describes the thorough knowledge of various hybrid vesicular systems.
AB - Anticancer drugs and diagnostics can be transported in nanoscale vesicles that provide a flexible platform. A hybrid nanoparticle, a nano assembly made up of many types of nanostructures, has the greatest potential to per-form these two activities simultaneously. Nanomedicine has shown the promise of vesicular carriers based on lipo-polymersomes, lipid peptides, and metallic hybrid nano-vesicle systems. However, there are significant limitations that hinder the clinical implementation of these systems at the commercial scale, such as low productivity, high ener-gy consumption, expensive setup, long process durations, and the current cancer therapies described in this article. Combinatorial hybrid systems can be used to reduce the above limitations. A greater therapeutic index and improved clinical results are possible with hybrid nanovesicular systems, which integrate the benefits of many carriers into a single structure. Due to their unique properties, cell-based drug delivery systems have shown tremendous benefits in the treatment of cancer. Nanoparticles (NPs) can benefit significantly from the properties of erythrocytes and plate-lets, which are part of the circulatory cells and circulate for a long time. Due to their unique physicochemical proper-ties, nanomaterials play an essential role in cell-based drug delivery. Combining the advantages of different nano-materials and cell types gives the resulting delivery systems a wide range of desirable properties. NPs are next-generation core-shell nanostructures that combine a lipid shell with a polymer core. The fabrication of lipid-polymer hybrid NPs has recently undergone a fundamental shift, moving from a two-step to a one-step technique based on the joint self-assembly of polymers and lipids. Oncologists are particularly interested in this method as a combinatorial drug delivery platform because of its two-in-one structure. This article addresses various preparative methods for the preparation of hybrid nano-vesicular systems. It also discusses the cellular mechanism of hybrid nano-vesicular systems and describes the thorough knowledge of various hybrid vesicular systems.
KW - Anticancer hybrid vesicular
KW - biocompatibility
KW - cellular mechanism
KW - nanomedicines
KW - preparative method
KW - specific targeting
UR - http://www.scopus.com/inward/record.url?scp=85145491768&partnerID=8YFLogxK
U2 - 10.2174/1389200223666220627110049
DO - 10.2174/1389200223666220627110049
M3 - Review article
C2 - 35761494
AN - SCOPUS:85145491768
SN - 1389-2002
VL - 23
SP - 757
EP - 780
JO - Current Drug Metabolism
JF - Current Drug Metabolism
IS - 9
ER -